Biomarin Pharmaceutical Inc (BMRN)
70.58
+0.34
(+0.48%)
USD |
NASDAQ |
Sep 27, 16:00
70.59
+0.01
(+0.01%)
After-Hours: 20:00
Biomarin Pharmaceutical Accounts Receivable (Quarterly): 691.23M for June 30, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 691.23M |
March 31, 2024 | 637.16M |
December 31, 2023 | 633.70M |
September 30, 2023 | 572.50M |
June 30, 2023 | 610.22M |
March 31, 2023 | 597.91M |
December 31, 2022 | 461.32M |
September 30, 2022 | 419.62M |
June 30, 2022 | 466.51M |
March 31, 2022 | 430.15M |
December 31, 2021 | 373.40M |
September 30, 2021 | 374.94M |
June 30, 2021 | 424.42M |
March 31, 2021 | 396.10M |
December 31, 2020 | 448.35M |
September 30, 2020 | 411.71M |
June 30, 2020 | 381.22M |
March 31, 2020 | 396.38M |
December 31, 2019 | 377.40M |
September 30, 2019 | 402.97M |
June 30, 2019 | 377.15M |
March 31, 2019 | 393.43M |
December 31, 2018 | 342.63M |
September 30, 2018 | 384.34M |
June 30, 2018 | 363.57M |
Date | Value |
---|---|
March 31, 2018 | 318.39M |
December 31, 2017 | 261.36M |
September 30, 2017 | 251.89M |
June 30, 2017 | 238.34M |
March 31, 2017 | 230.25M |
December 31, 2016 | 215.28M |
September 30, 2016 | 215.89M |
June 30, 2016 | 214.16M |
March 31, 2016 | 180.75M |
December 31, 2015 | 164.96M |
September 30, 2015 | 148.95M |
June 30, 2015 | 186.08M |
March 31, 2015 | 175.74M |
December 31, 2014 | 144.47M |
September 30, 2014 | 121.40M |
June 30, 2014 | 122.28M |
March 31, 2014 | 110.46M |
December 31, 2013 | 117.82M |
September 30, 2013 | 124.74M |
June 30, 2013 | 115.06M |
March 31, 2013 | 120.34M |
December 31, 2012 | 109.07M |
September 30, 2012 | 117.29M |
June 30, 2012 | 100.75M |
March 31, 2012 | 105.83M |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
373.40M
Minimum
Dec 2021
691.23M
Maximum
Jun 2024
475.36M
Average
427.28M
Median
Accounts Receivable (Quarterly) Benchmarks
Alnylam Pharmaceuticals Inc | 309.48M |
Bristol-Myers Squibb Co | 9.746B |
Eli Lilly and Co | 11.03B |
Repligen Corp | 123.24M |
Bioventus Inc | 137.30M |